- Trial phase
- Phase 2 completed; preparing for Phase 3 (SPECTRUM program)
- Time to market
- If the IND is cleared by early 2027 and Phase 3 SPECTRUM program proceeds smoothly, potential FDA submission could be 2029-2030, assuming positive pivotal data. The drug is still pre-Phase 3.
- Why 7/10
- The next hard catalyst is the NDV-01 IND submission, expected by year-end 2026 (within ~6 weeks). NDV-01 is Relmada's lead asset and primary value driver, but the IND submission is a regulatory milestone rather than a pivotal readout, and the company also has a second program (sepranolone).
The next catalyst is the NDV-01 IND submission, which Relmada expects by year-end 2026 (about 6 weeks away). A successful IND clearance would allow the Phase 3 SPECTRUM program to begin, while any delay or FDA clinical hold would be sharply negative. The Q4 2026 corporate update will likely confirm the submission status.
Price Chart
Executive Summary
NDV-01 is Relmada Therapeutics' (Nasdaq: RLMD) lead drug candidate for non-muscle invasive bladder cancer (NMIBC). Phase 2 data showed a 76% durable complete response rate at 12 months, with 86% of responders maintaining response at 18 months. The company is on track to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM registrational program. The company raised $160M in a March 2026 PIPE and held $202.1M in cash as of Q3 2026, funding operations through 2029. Relmada previously lost ~80% of its value in December 2024 when its depression drug REL-1017 failed a Phase 3 futility analysis, making NDV-01 the company's primary value driver and a high-stakes pivot into oncology.
How It Works
NDV-01 is an investigational therapy for non-muscle invasive bladder cancer (NMIBC), a type of bladder cancer that has not spread into the deeper muscle layers. The exact mechanism of action is not publicly detailed in available sources, but it is being developed as a potential treatment for patients with high-risk NMIBC, an area with significant unmet need where the standard of care (BCG therapy) has high recurrence rates.
Trial Status
Phase 2 study in NMIBC completed with positive 12-month and 18-month durability data. The company is preparing to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM registrational program, which includes two independent pathways for registration.
The Two-Sided Case
Upcoming Catalysts
- NDV-01 IND submission expected by year-end 2026 (Q4 2026)
- FDA 30-day IND review period following submission (early 2027)
- Initiation of Phase 3 SPECTRUM program (mid-2027)
- Sepranolone IND submission also expected by year-end 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
RELMADA THERAPEUTICS, INC. 8-K RLMD ·Originating report